US 12,391,740 B2
Compositions and methods for treating cancer with anti-BCMA immunotherapy
Dina Schneider, Potomac, MD (US); Zhongyu Zhu, Frederick, MD (US); Boro Dropulic, Ellicott City, MD (US); Bang Khoa Vu, Frederick, MD (US); and Leah Marie Alabanza, Montgomery Village, MD (US)
Assigned to LENTIGEN TECHNOLOGY, INC., Gaithersburg, MD (US)
Filed by LENTIGEN TECHNOLOGY, INC., Gaithersburg, MD (US)
Filed on Jun. 2, 2021, as Appl. No. 17/337,018.
Application 17/337,018 is a continuation of application No. 16/888,020, filed on May 29, 2020, granted, now 11,052,112.
Claims priority of provisional application 62/854,574, filed on May 30, 2019.
Prior Publication US 2021/0361709 A1, Nov. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/85 (2006.01); A61K 35/17 (2025.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61P 35/00 (2006.01); A61P 35/02 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C12N 5/0783 (2010.01); C12N 15/63 (2006.01)
CPC C07K 14/7051 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 40/4215 (2025.01); A61P 35/00 (2018.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 16/2878 (2013.01); C12N 5/0636 (2013.01); A61K 2239/31 (2023.05); A61K 2239/48 (2023.05); C12N 15/63 (2013.01)] 23 Claims
 
1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR) comprising the amino acid sequence of SEQ ID NO: 78.